Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 626.00
Bid: 622.00
Ask: 628.00
Change: 4.00 (0.64%)
Spread: 6.00 (0.965%)
Open: 630.00
High: 638.00
Low: 624.00
Prev. Close: 622.00
BMY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bloomsbury playwright Jon Fosse wins Nobel Prize

9 Oct 2023 13:00

RNS Number : 4421P
Bloomsbury Publishing PLC
09 October 2023
 

 

Bloomsbury playwright Jon Fosse wins Nobel Prize in Literature

 

 

9 October, LONDON: Bloomsbury, the leading independent publisher, is pleased to announce that its author Jon Fosse, the Norwegian playwright, has won the 2023 Nobel Prize in literature "for his innovative plays and prose which give voice to the unsayable."

 

According to the citation of the Nobel committee, "his immense oeuvre, written in Norwegian Nynorsk and spanning a variety of genres consists of a wealth of plays, novels, poetry collections, essays, children's books and translations. While he is today one of the most widely performed playwrights in the world, he has also become increasingly recognised for his prose."

 

Jon Fosse has won many European awards and in 2007 he was made a Knight in France's National Order of Merit. He has written 40 plays, performed around the world in different languages, including the Septology series of novels, Aliss at the Fire, Melancholy and A Shining.

 

Winning the 2023 Nobel Prize for Literature, Jon Fosse becomes the 8th Nobel-Prize winning writer from Bloomsbury's imprint Methuen Drama, joining Peter Handke, Dario Fo, Toni Morrison, Wole Soyinka, Luigi Pirandello, John Galsworthy and George Bernard Shaw.

 

Fosse's first English language play collection was published by Oberon Books, acquired by Bloomsbury in 2019, which has now published six collections of his plays, alongside single playtexts including I Am The Wind and The Dead Dogs to coincide with major premiere productions in London.

 

Nigel Newton, Chief Executive of Bloomsbury, commented: "Jon Fosse's remarkable body of dramatic work was fiercely championed by Oberon Books, now part of Methuen Drama, within the Bloomsbury Academic division, since the publication of his first English language play collection in 2002. Since then, we have published five further anthologies, totalling over 30 plays and a number of standalone translations and adaptations by some of the world's most successful contemporary dramatists. While he is one of the most-performed writers in Europe, his dramatic canon is less well-known on U.K. stages and we hope that with this historic win, the English speaking theatre community will discover and fall for his unique linguistic style, poetic naturalism and formally inventive work that manages to be both existential and life-affirming."

 

 

-ENDS-

 

For further information please contact:

 

Hudson Sandler

 

+44 (0) 20 7796 4133

Dan de Belder/Emily Brooker

 

bloomsbury@hudsonsandler.com

 

 

Bloomsbury Publishing Plc

Bloomsbury is a leading independent publisher of fiction, non-fiction, children's, specialist, academic and professional titles, listed on the London Stock Exchange. It is one of the few publishers with a portfolio that includes both general and academic publishing. Bloomsbury's ambitious growth story has seen the Group become a significant global publisher with offices in the UK, US, Australia and India.

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUPGUWUUPWGGB
Date   Source Headline
14th Jun 20245:01 pmRNSAnnual Financial Report
14th Jun 20241:48 pmRNSBoard Appointment
29th May 20247:00 amRNSAcquisition
23rd May 20247:00 amRNSChairman Succession Announcement
23rd May 20247:00 amRNSAudited Preliminary Results
20th May 20247:00 amRNSInvestor Presentation
16th Feb 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
14th Feb 20247:00 amRNSTrading Update
1st Feb 20243:11 pmRNSBloomsbury launches latest Sarah J. Maas novel
15th Jan 20247:00 amRNSBloomsbury Appoints Head of Investor Relations
12th Jan 202411:45 amRNSHolding(s) in Company
9th Jan 20244:10 pmRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
15th Nov 20237:00 amRNSBlocklisting Application
31st Oct 20237:00 amRNSInvestor Presentation
26th Oct 20237:00 amRNSUnaudited Interim Results
9th Oct 20231:00 pmRNSBloomsbury playwright Jon Fosse wins Nobel Prize
22nd Sep 20231:26 pmRNSDirector/PDMR Shareholdings - Correction
14th Sep 20237:00 amRNSBloomsbury launches new book by Katherine Rundell
5th Sep 20237:00 amRNSDirector/PDMR Shareholding
1st Sep 20232:05 pmRNSDirector/PDMR Shareholding
30th Aug 20231:56 pmRNSDirector/PDMR Shareholding
29th Aug 20232:11 pmRNSDirector/PDMR Shareholding
23rd Aug 20237:00 amRNSHolding(s) in Company
22nd Aug 20238:00 amRNSBloomsbury enjoys bestseller success
17th Aug 20234:40 pmRNSBLOCK LISTING SIX MONTHLY RETURN
18th Jul 20235:13 pmRNSResults of the 2023 Annual General Meeting
18th Jul 20237:00 amRNSAGM Trading Update
23rd Jun 20232:29 pmRNSAnnual Financial Report
2nd Jun 202311:50 amRNSDirector/PDMR Shareholding
1st Jun 20239:34 amRNSDirector Declaration
31st May 20232:04 pmRNSInvestor Presentation
31st May 20237:00 amRNSAudited Preliminary Results
16th May 20237:00 amRNSNotice of Capital Markets Event
2nd May 20232:43 pmRNSNotice of Results
12th Apr 20233:16 pmRNSHolding(s) in Company
11th Apr 202310:03 amRNSHolding(s) in Company
15th Mar 20237:00 amRNSTrading Update
1st Mar 20237:00 amRNSNotice of Trading Update
17th Feb 20232:09 pmRNSBLOCK LISTING SIX MONTHLY RETURN
11th Jan 20239:08 amRNSHolding(s) in Company
18th Nov 20222:29 pmRNSHolding(s) in Company
14th Nov 20225:16 pmRNSHolding(s) in Company
2nd Nov 20222:56 pmRNSDirector/PDMR Shareholding
1st Nov 20225:16 pmRNSHolding(s) in Company
31st Oct 20227:00 amRNSInvestor Presentation
27th Oct 20221:02 pmEQSBloomsbury Publishing pleased with 'surge in the numbers'
26th Oct 20227:00 amRNSUnaudited Interim Results
14th Oct 202212:41 pmRNSHolding(s) in Company
4th Oct 20224:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.